Background Excessive use of short-acting β2 agonists (SABA) in patients with asthma
continues to be a notable concern due to its link to higher mortality rates. Global relevance of …

Objective Short-acting β2-agonist (SABA) overuse is associated with poor asthma outcomes;
however, the extent of SABA use in Thailand is largely unknown. As part of the SABA use IN …

Background The extent of short-acting Beta-2-agonist (β 2-agonist)(SABA) use across Asian
countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we …

Abstract Objective The SABINA (SABA use IN Asthma) program was initiated to describe
short-acting β2-agonists (SABA) prescription patterns and assess the impact of its over …

Background Although short-acting β2-agonist (SABA) overuse is associated with poor
treatment outcomes, data on SABA use in the Middle East are lacking. Research design and …

Objectives To evaluate asthma characteristics and treatment patterns, including short-acting
β2-agonist (SABA) prescriptions, in primary and specialist care in the Singapore cohort of …

Background Overuse of short-acting β 2-agonists (SABA) may indicate poor asthma control
and adverse health outcomes. Contemporary population-based data on use, risk factors and …

Background: Safety concerns around the use of as-needed short-acting β 2-agonist (SABA)
monotherapy in asthma management warrant evaluation. The SABa use IN Asthma …

Background Over-reliance on short-acting β2-agonists (SABAs) is associated with poor
asthma outcomes. However, the extent of SABA use in Turkey is unclear owing to a lack of …

Background The overuse of short-acting β2-agonists (SABA) is associated with poor asthma
control. However, data on SABA use in the Gulf region are limited. Herein, we describe …